AGP Picks
View all

California Health Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on California Health Watch.

Press releases published on May 14, 2026

Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market
AVITA Medical Reports First Quarter 2026 Financial Results
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026
CapsoVision Reports First Quarter 2026 Financial Results
BioStem Technologies Reports First Quarter 2026 Financial Results
Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
Alignment Health Plan Recognized as One of Four Medicare Advantage Prescription Drug Plans in the U.S. for 2026 Excellence in Quality
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
Elutia to Present at the 16th Annual LD Micro Invitational on May 18th
Heartflow Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold
Historical DNA connects 1.3 million living relatives to 17th-century Maryland settlers and may have identified the colony’s second governor
Award-Winning Film ‘An Inconvenient Study’ Being Blocked By Verizon
Rarecells Recognized Among Top 5 Disruptive Health Technologies with the Potential to Change the World by Maynooth University’s Innovation Value Institute
Imviva Biotech Presents Data Demonstrating Durable Clinical Responses from Ongoing Phase 1/2 Study of CTA313 in Systemic Lupus Erythematosus at ASGCT 2026
Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

California Health Watch

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.